Home | Business News | Browse by Publication | M | M2 Presswire

Daily Market Movers Digest Midday Stock Alerts, Thursday, July 27th, XKEM, ETYN, IGAI, IDCO, CKYS.

Article Excerpt
M2 PRESSWIRE-27 July 2006-OTCPicks.com: Daily Market Movers Digest Midday Stock Alerts, Thursday, July 27th, XKEM, ETYN, IGAI, IDCO, CKYS(C)1994-2006 M2 COMMUNICATIONS LTD

RDATE:27072006

Today our stock watch alerts today include Featured Profiles for Xechem International, Inc. (OTCBB: XKEM), Enterayon, Inc. (OTC: ETYN), and stock alerts for IGIA, Inc. (OTCBB: IGAI), Id-Confirm, Inc. (OTCBB:IDCO), CyberKey Solutions, Inc. (OTC: CKYS)

FEATURED STOCK PROFILE

XECHEM INTERNATIONAL, INC. (OTCBB: XKEM)

Detailed Quote: http://www.otcpicks.com/quotes/XKEM.php

View Profile: http://www.otcpicks.com/profiles/xkem/index.php

Xechem International, Inc. (OTCBB: XKEM) is a development stage biopharmaceutical company focusing on anticancer, antiviral (including AIDS), antifungal, Sickle Cell Disease (SCD), antimalarial and antibacterial products from natural sources, including microbial and marine organisms. Xechem's mission is to bring relief to the millions of people who suffer from these diseases. Its focus is on the development of phyto-pharmaceuticals and other proprietary technologies, including those used in the treatment of orphan diseases. Its primary attention and resources are currently being directed toward the development and commercial launch of its Sickle Cell drug, NICOSAN(TM)/HEMOXIN(TM), which has shown efficacy in the treatment of SCD.

XKEM News:

July 26 - Demand for New Sickle Cell Drug NICOSAN(TM) Far Exceeds Supply; Xechem Nigeria Accelerates Construction of Commercial Scale Production Facility

Xechem International, Inc. (OTCBB: XKEM) announced today that response to the first limited sales and distribution of NICOSAN(TM), its new product for the prophylactic management of Sickle Cell Disease (SCD), by its subsidiary, Xechem Pharmaceuticals Nigeria, Ltd. (Xechem Nigeria), has been far greater than anticipated. Xechem Nigeria has broken ground for a new state-of-the-art commercial scale production facility and accelerated the facility's construction schedule. Xechem Nigeria, which received regulatory approval for NICOSAN(TM), its first major breakthrough "Natural Herbal Drug," on July 3rd, 2006 from the National Agency for Food and Drug Administration and Control of Nigeria (NAFDAC), has been producing the drug in limited quantities at its pilot scale facility in Abuja, Nigeria.

Xechem Nigeria's new commercial scale facility will have capacity to meet the demand of Nigeria and other African countries. Nigeria alone has 4 million sickle cell disease patients. The new facility will also be able to supply the drug for the clinical trials in the United States and the European Union.

NICOSAN(TM) was launched by the President of Nigeria, His Excellency Chief Olusegun Obasanjo on July 6th, 2006 at SHESTCO Complex. Immediately after the launch ceremony Xechem Nigeria has started direct sales of NICOSAN(TM) in Abuja, the Federal Capital Territory of Nigeria.

The drug is taken through one-a-day capsules which, once started, must be taken daily by the patient. The current price for a months supply for Adults is established at N 3,000 Naira (approx. US $23) and for Pediatrics at N 2,400 Naira (approx. US $18), respectively. Xechem is also accepting mail orders for the drug from other States within Nigeria.

The financing for this first phase of construction was supplied by Nigerian Export-Import (NEXIM) Bank, which loaned Xechem Nigeria N150 Million Naira (US$1.2 million) in June of this year. Xechem estimates that the expanded facility will be fully operational within 9 months.

Dr. Ramesh Pandey, Chairman and CEO of the Xechem Companies said, "This is a very exciting time for Xechem and one that has been more than four years in the making. Getting NICOSAN(TM) approved for the prophylactic management of Sickle Cell Disease (SCD) was a major milestone which changes Xechem from a research and development company to a full scale business venture with NICOSAN(TM) to market.

"This also required the construction of a full scale production facility, on...